董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Kevin Buchi | 男 | Director | 60 | 8.55万美元 | 未持股 | 2016-04-15 |
| Deepika R. Pakianathan | 女 | Director | 51 | 8.55万美元 | 未持股 | 2016-04-15 |
| Thomas B. King | 男 | Chief Executive Officer, President and Director | 61 | 85.22万美元 | 未持股 | 2016-04-15 |
| Deepika R. Pakianathan | 男 | Director | 51 | 未披露 | 未持股 | 2016-04-15 |
| J. Leighton Read | 男 | Director | 65 | 8.55万美元 | 未持股 | 2016-04-15 |
| Gordon Ringold | 男 | Director | 65 | 9.75万美元 | 未持股 | 2016-04-15 |
| Isaac Stein | 男 | Director | 69 | 未披露 | 未持股 | 2016-04-15 |
| Isaac Stein | 男 | Director | 69 | 11.35万美元 | 未持股 | 2016-04-15 |
| Joseph L. Turner | 男 | Director | 64 | 10.55万美元 | 未持股 | 2016-04-15 |
| J. Kevin Buchi | 男 | Director | 60 | 未披露 | 未持股 | 2016-04-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edwin S. Kamemoto | 男 | Executive Vice President, R&D, Regulatory and Quality | 62 | 48.62万美元 | 未持股 | 2016-04-15 |
| Thomas B. King | 男 | Chief Executive Officer, President and Director | 61 | 85.22万美元 | 未持股 | 2016-04-15 |
董事简历
中英对照 | 中文 | 英文- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
Deepika R. Pakianathan, Ph.D., has served as a member of Theravance Biopharma, Inc. board of directors since July 2020. Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a privately-held pharmaceuticals company, since September 2019. From 2007 to 2019 Dr. Pakianathan served on the board of directors of Alder Pharmaceuticals, Inc. and from 2004 to 2016 Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc. From 1998 to 2001 Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company. From 1993 to 1997 Dr. Pakianathan served as a postdoctoral scientist in the Immunology Department at Genentech Corporation. Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., Mereo Biopharma Group PLC and FS Development Corp. II, an SPAC. Dr. Pakianathan holds an M.S. and a Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and an M.Sc. from The Cancer Research Institute at the University of Bombay, India. - Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
- Deepika R. Pakianathan, Ph.D., has served as a member of Theravance Biopharma, Inc. board of directors since July 2020. Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a privately-held pharmaceuticals company, since September 2019. From 2007 to 2019 Dr. Pakianathan served on the board of directors of Alder Pharmaceuticals, Inc. and from 2004 to 2016 Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc. From 1998 to 2001 Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company. From 1993 to 1997 Dr. Pakianathan served as a postdoctoral scientist in the Immunology Department at Genentech Corporation. Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., Mereo Biopharma Group PLC and FS Development Corp. II, an SPAC. Dr. Pakianathan holds an M.S. and a Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and an M.Sc. from The Cancer Research Institute at the University of Bombay, India.
- Thomas B. King
-
Thomas B. King， 2003年6月以来，担任总裁、首席执行官以及董事会的成员。从2002年9月到2003年4月，担任Cognetix生物制药开发公司的主席、首席执行官和董事会成员。从1994年1月至2001年2月，他担任Anesta上市医药公司的各种高管职位；从1997年1月至2000年10月，他担任董事长和首席执行官，他是董事会的成员，直到它被Cephalon生物制药上市公司收购。他获得堪萨斯大学的工商管理硕士学位和麦克弗森学院的化学学士学位。
Thomas B. King has served as a director of the Company since May 24 2017. Mr. King served as the interim Chief Executive Officer of the Company from December 31 2017 to April 30 2018 and as interim President of the Company from April 30 2018 to May 30 2018. He has served as an independent biotechnology consultant and advisor since August 2016. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc., Faraday Pharmaceuticals, Inc. and Satsuma Pharmaceuticals, Inc., all privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business. - Thomas B. King， 2003年6月以来，担任总裁、首席执行官以及董事会的成员。从2002年9月到2003年4月，担任Cognetix生物制药开发公司的主席、首席执行官和董事会成员。从1994年1月至2001年2月，他担任Anesta上市医药公司的各种高管职位；从1997年1月至2000年10月，他担任董事长和首席执行官，他是董事会的成员，直到它被Cephalon生物制药上市公司收购。他获得堪萨斯大学的工商管理硕士学位和麦克弗森学院的化学学士学位。
- Thomas B. King has served as a director of the Company since May 24 2017. Mr. King served as the interim Chief Executive Officer of the Company from December 31 2017 to April 30 2018 and as interim President of the Company from April 30 2018 to May 30 2018. He has served as an independent biotechnology consultant and advisor since August 2016. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc., Faraday Pharmaceuticals, Inc. and Satsuma Pharmaceuticals, Inc., all privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan， 2004年11月以来，担任我们的董事会的成员。自2001年以来，他德尔福合资企业担任管理成员，该公司为风险资本公司，专注于医疗投资。从1998年到2001年，他担任JPMorgan的生物技术高级银行家。加入JPMorgan之前，从1997年到1998年，他是创世纪商人集团的私人投资伙伴关系研究分析师；从1993年到1997年，他担任基因泰克公司的博士后科学家。从2013年4月到现在，他也是Karyopharm Therapeutics公司的董事会成员，该公司为上市医药公司。从2008年12月到现在，他担任OncoMed制药公司的董事会成员，该公司为一家公开上市的生物制药公司。Pakianathan获得了维克森林大学的免疫学博士学位和生物学硕士学位，以及孟买大学的生物物理学商科硕士学位和运筹学学位。
Deepika R. Pakianathan has served as a member of the Board since November 2004. Since 2001 Dr. Pakianathan has served as a managing member at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001 Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JPMorgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to 1998 and a post-doctoral scientist at Genentech, Inc. from 1993 to 1997. Dr. Pakianathan has served on the board of directors of Karyopharm Therapeutics, Inc., a publicly traded pharmaceutical company, since April 2013 and OncoMed Pharmaceuticals Inc., a publicly traded biopharmaceutical company since December 2008. - Deepika R. Pakianathan， 2004年11月以来，担任我们的董事会的成员。自2001年以来，他德尔福合资企业担任管理成员，该公司为风险资本公司，专注于医疗投资。从1998年到2001年，他担任JPMorgan的生物技术高级银行家。加入JPMorgan之前，从1997年到1998年，他是创世纪商人集团的私人投资伙伴关系研究分析师；从1993年到1997年，他担任基因泰克公司的博士后科学家。从2013年4月到现在，他也是Karyopharm Therapeutics公司的董事会成员，该公司为上市医药公司。从2008年12月到现在，他担任OncoMed制药公司的董事会成员，该公司为一家公开上市的生物制药公司。Pakianathan获得了维克森林大学的免疫学博士学位和生物学硕士学位，以及孟买大学的生物物理学商科硕士学位和运筹学学位。
- Deepika R. Pakianathan has served as a member of the Board since November 2004. Since 2001 Dr. Pakianathan has served as a managing member at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001 Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JPMorgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to 1998 and a post-doctoral scientist at Genentech, Inc. from 1993 to 1997. Dr. Pakianathan has served on the board of directors of Karyopharm Therapeutics, Inc., a publicly traded pharmaceutical company, since April 2013 and OncoMed Pharmaceuticals Inc., a publicly traded biopharmaceutical company since December 2008.
- J. Leighton Read
-
J. Leighton Read，医学博士， 2004年11月以来，担任我们的董事会成员。从2001年到2007年，他担任Alloy Ventures四个基金合金企业的管理成员，后来成为合资企业的合作伙伴。他创立了Aviron，，一家生物制药公司，并担任董事长兼首席执行官， 1999年他担任负责人，直到2002年Aviron被MedImmune有限责任公司收购。1989年，他同Affymax NV生物制药公司合并。他因为技术贡献获得了co-inventing Affymetrix GeneChip的几个奖项。他获得了圣安东尼奥德克萨斯大学健康科学中心的博士学位，完成了他在杜克大学的内科培训和Peter Bent Brigham医院的实践，并获得了莱斯大学心理学和生物学学士学位。
J. Leighton Read has served as a member of the Board since November 2004. From 2001 until 2007 Dr. Read served as a Managing Member in four funds at Alloy Ventures, where he continues as a Venture Partner. Dr. Read founded Aviron, a biopharmaceutical company, and served as its Chairman and Chief Executive Officer until 1999 and as a director from 1992 until its acquisition by MedImmune, LLC in 2002. In 1989 Dr. Read co-founded Affymax NV, a biopharmaceutical company. Dr. Read has received several awards for co-inventing the technology underlying the Affymetrix GeneChip. Dr. Read received an M.D. from the University of Texas Health Science Center at San Antonio and completed his training in internal medicine at Duke University and the Peter Bent Brigham Hospital, and received a B.S. in psychology and biology from Rice University. - J. Leighton Read，医学博士， 2004年11月以来，担任我们的董事会成员。从2001年到2007年，他担任Alloy Ventures四个基金合金企业的管理成员，后来成为合资企业的合作伙伴。他创立了Aviron，，一家生物制药公司，并担任董事长兼首席执行官， 1999年他担任负责人，直到2002年Aviron被MedImmune有限责任公司收购。1989年，他同Affymax NV生物制药公司合并。他因为技术贡献获得了co-inventing Affymetrix GeneChip的几个奖项。他获得了圣安东尼奥德克萨斯大学健康科学中心的博士学位，完成了他在杜克大学的内科培训和Peter Bent Brigham医院的实践，并获得了莱斯大学心理学和生物学学士学位。
- J. Leighton Read has served as a member of the Board since November 2004. From 2001 until 2007 Dr. Read served as a Managing Member in four funds at Alloy Ventures, where he continues as a Venture Partner. Dr. Read founded Aviron, a biopharmaceutical company, and served as its Chairman and Chief Executive Officer until 1999 and as a director from 1992 until its acquisition by MedImmune, LLC in 2002. In 1989 Dr. Read co-founded Affymax NV, a biopharmaceutical company. Dr. Read has received several awards for co-inventing the technology underlying the Affymetrix GeneChip. Dr. Read received an M.D. from the University of Texas Health Science Center at San Antonio and completed his training in internal medicine at Duke University and the Peter Bent Brigham Hospital, and received a B.S. in psychology and biology from Rice University.
- Gordon Ringold
-
Gordon Ringold, 2014年6月被任命为Ardelyx, Inc.董事会成员。他曾担任Quadriga BioSciences, Inc.(一家生物技术公司)的总裁兼首席执行官(2015年1月以来)。从2000年3月到2013年12月，他担任Alavita, Inc.(生物技术公司)的董事长兼首席执行官。从2001年6月到2016年9月，他担任Alexza Pharmaceuticals, Inc.的董事。纳斯达克:ALXA。1997年至2013年，他担任上市生物制药公司Maxygen, Inc.的董事会成员。在加入斯坦福大学医学院药学系之前，他获得了加州大学旧金山分校Harold Varmus博士实验室的微生物学博士学位。他还获得了加州大学圣克鲁斯分校(University of California, Santa Cruz)的生物学学士学位。
Gordon Ringold was appointed to Ardelyx, Inc. board of directors in June 2014. Dr. Ringold has served as the President and CEO of Quadriga BioSciences, Inc., a biotechnology company, since January 2015. From March 2000 to December 2013 Dr. Ringold served as Chairman and Chief Executive Officer of Alavita, Inc., a biotechnology company. From June 2001 until September 2016 Dr. Ringold served as a director of Alexza Pharmaceuticals, Inc. NASDAQ: ALXA. From 1997 to 2013 Dr. Ringold served as a member of the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company. Dr. Ringold received a Ph.D. in microbiology from University of California, San Francisco, in the laboratory of Dr. Harold Varmus before joining the Stanford University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from the University of California, Santa Cruz. - Gordon Ringold, 2014年6月被任命为Ardelyx, Inc.董事会成员。他曾担任Quadriga BioSciences, Inc.(一家生物技术公司)的总裁兼首席执行官(2015年1月以来)。从2000年3月到2013年12月，他担任Alavita, Inc.(生物技术公司)的董事长兼首席执行官。从2001年6月到2016年9月，他担任Alexza Pharmaceuticals, Inc.的董事。纳斯达克:ALXA。1997年至2013年，他担任上市生物制药公司Maxygen, Inc.的董事会成员。在加入斯坦福大学医学院药学系之前，他获得了加州大学旧金山分校Harold Varmus博士实验室的微生物学博士学位。他还获得了加州大学圣克鲁斯分校(University of California, Santa Cruz)的生物学学士学位。
- Gordon Ringold was appointed to Ardelyx, Inc. board of directors in June 2014. Dr. Ringold has served as the President and CEO of Quadriga BioSciences, Inc., a biotechnology company, since January 2015. From March 2000 to December 2013 Dr. Ringold served as Chairman and Chief Executive Officer of Alavita, Inc., a biotechnology company. From June 2001 until September 2016 Dr. Ringold served as a director of Alexza Pharmaceuticals, Inc. NASDAQ: ALXA. From 1997 to 2013 Dr. Ringold served as a member of the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company. Dr. Ringold received a Ph.D. in microbiology from University of California, San Francisco, in the laboratory of Dr. Harold Varmus before joining the Stanford University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from the University of California, Santa Cruz.
- Isaac Stein
-
Isaac Stein，2001年6月以来，担任我们的董事会的成员。1982年11月以来，他担任斯坦威弗利Associates私人投资公司的总裁。他也是斯坦福大学的名誉董事会主席。从1997年到2013年，他担任Maxygen公司的董事会成员，该公司为一家上市的生物制药公司。他也是美国Balanced Fund公司的负责人，International Growth and Income Fund股份公司的负责人以及美国收益基金股份公司的负责人，该公司为美国共同极尽家族的成员。他获得斯坦福大学的工商管理硕士学位和法学博士学位，以及科尔盖特大学的数理经济学学士学位。
Isaac Stein has served as a member of the Board since June 2001. From November 1982 to December 2015 Mr. Stein was President of Waverley Associates, Inc., a private investment firm. He is also the emeritus Chairman of the Board of Trustees of Stanford University. From 1997 to 2013 Mr. Stein served on the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company. Mr. Stein is also a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc., and The Income Fund of America, Inc. part of the American Funds family of mutual funds. - Isaac Stein，2001年6月以来，担任我们的董事会的成员。1982年11月以来，他担任斯坦威弗利Associates私人投资公司的总裁。他也是斯坦福大学的名誉董事会主席。从1997年到2013年，他担任Maxygen公司的董事会成员，该公司为一家上市的生物制药公司。他也是美国Balanced Fund公司的负责人，International Growth and Income Fund股份公司的负责人以及美国收益基金股份公司的负责人，该公司为美国共同极尽家族的成员。他获得斯坦福大学的工商管理硕士学位和法学博士学位，以及科尔盖特大学的数理经济学学士学位。
- Isaac Stein has served as a member of the Board since June 2001. From November 1982 to December 2015 Mr. Stein was President of Waverley Associates, Inc., a private investment firm. He is also the emeritus Chairman of the Board of Trustees of Stanford University. From 1997 to 2013 Mr. Stein served on the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company. Mr. Stein is also a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc., and The Income Fund of America, Inc. part of the American Funds family of mutual funds.
- Isaac Stein
-
Isaac Stein自1998年6月以来担任公司的董事会主席，自2009年9月以来担任执行董事长，自1996年5月以来担任董事。他被任命为公司的首席执行官和首席财务官，于2013年7月1日起生效。他自1982年11月以来担任Waverley Associates, Inc.（私人投资公司）的总裁。他是Stanford University的理事会成员和名誉主席，是American Balanced Fund, Inc., International Growth and Income Fund, Inc.和The Income Fund of America, Inc.(所有都隶属于the Capital Group Companies和Alexza Pharmaceuticals, Inc.)的董事。他也是the James Irvine Foundation的董事。他获得Stanford University的工商管理硕士学位和法学博士学位以及Colgate University的数理经济学学士学位。
Isaac Stein has served as the Company’s Chairman of the Board of Directors since June 1998 and as Executive Chairman of the Board of Directors since September 2009 and has been a director since May 1996. Mr. Stein also has been appointed as the Company’s Chief Executive Officer and Chief Financial Officer, effective as of July 1 2013. Since November 1982 Mr. Stein has been President of Waverley Associates, Inc., a private investment firm. He is a member of and the emeritus Chairman of the Board of Trustees of Stanford University and is a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc. and The Income Fund of America, Inc. all affiliated with the Capital Group Companies, and Alexza Pharmaceuticals, Inc. He is also a director of the James Irvine Foundation. Mr. Stein received an M.B.A. and J.D. from Stanford University and a B.A. in mathematical economics from Colgate University. - Isaac Stein自1998年6月以来担任公司的董事会主席，自2009年9月以来担任执行董事长，自1996年5月以来担任董事。他被任命为公司的首席执行官和首席财务官，于2013年7月1日起生效。他自1982年11月以来担任Waverley Associates, Inc.（私人投资公司）的总裁。他是Stanford University的理事会成员和名誉主席，是American Balanced Fund, Inc., International Growth and Income Fund, Inc.和The Income Fund of America, Inc.(所有都隶属于the Capital Group Companies和Alexza Pharmaceuticals, Inc.)的董事。他也是the James Irvine Foundation的董事。他获得Stanford University的工商管理硕士学位和法学博士学位以及Colgate University的数理经济学学士学位。
- Isaac Stein has served as the Company’s Chairman of the Board of Directors since June 1998 and as Executive Chairman of the Board of Directors since September 2009 and has been a director since May 1996. Mr. Stein also has been appointed as the Company’s Chief Executive Officer and Chief Financial Officer, effective as of July 1 2013. Since November 1982 Mr. Stein has been President of Waverley Associates, Inc., a private investment firm. He is a member of and the emeritus Chairman of the Board of Trustees of Stanford University and is a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc. and The Income Fund of America, Inc. all affiliated with the Capital Group Companies, and Alexza Pharmaceuticals, Inc. He is also a director of the James Irvine Foundation. Mr. Stein received an M.B.A. and J.D. from Stanford University and a B.A. in mathematical economics from Colgate University.
- Joseph L. Turner
-
Joseph L. Turner，任2010年7月以来，担任我们的董事会成员。目前，他担任Corcept Therapeutics公司、Kythera Biopharmaceuticals公司和Sophiris生物制药公司的董事会和审计委员会主席。2012年，他担任Allos Therapeutics上市医药公司的董事会和审计委员会的主席，直到2012年9月它被Spectrum Pharmaceuticals公司收购。从2010年到2012年，他担任QLT上市生物科技公司的董事会和审计委员会的成员。2008年，他担任SGX Pharmaceuticals上市医药公司的董事和审计委员会成员。1999年，他加入Myogen生物制药上市公司，担任首席财务官，直到2006年它被吉利德科技公司收购。之前，他担任Centaur Pharmaceuticals公司的首席财务官，Cortech公司的首席财务官和副董事长。自2009年以来，他曾在斯沃斯莫尔学院的担任董事会主席，2010年6月，他加入财政委员会、学术事务委员会和学生事务委员会。2013年6月，他是财产委员会成员。2013年，他加入科罗拉多大学医学院琳达Crnic唐氏综合症研究所的董事会。他获得北卡罗莱纳大学教堂山分校的工商管理硕士学位，科罗拉多大学的分子生物学硕士学位、斯沃斯莫尔学院的化学学士学位。
Joseph L. Turner has served as a member of our Board of Directors since February 2017. Mr. Turner currently serves on the board of directors of Arcutis Biotherapeutics, Inc., a publicly traded biopharmaceutical company, and Rainier Therapeutics, Inc. Prior to joining our Board of Directors, Mr. Turner served on the boards of directors and was the chair of the audit committees of Corcept Therapeutics, Inc., a publicly traded pharmaceutical company, from 2012 to May 2016 Kythera Biopharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2008 until Kythera’s acquisition by Allergan Inc. October 2015 and Sophiris Bio, a publicly traded pharmaceutical company from 2013 to May 2016. From July 2010 until its acquisition by Grupo Ferrer Internacional, S.A. in June 2016 Mr. Turner served on the board of directors and as a chair of the audit committee of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company. In 2012 Mr. Turner served on the board of directors and as chair of the audit committee of Allos Therapeutics, Inc., a publicly traded pharmaceutical company, until its acquisition by Spectrum Pharmaceuticals Inc. in September 2012. From 2010 through 2012 he served on the board of directors and as a member of the audit committee of QLT Inc., a publicly traded biotechnology company. In 2008 Mr. Turner served as a director and member of the audit committee of SGX Pharmaceuticals Inc., a publicly traded pharmaceutical company. Mr. Turner served as chief financial officer at Myogen, Inc., a publicly traded biopharmaceutical company, from 1999 until it was acquired by Gilead Sciences in 2006. Previously, Mr. Turner was the chief financial officer at Centaur Pharmaceuticals, Inc. and served as chief financial officer and vice president, finance and administration at Cortech, Inc. Since 2009 Mr. Turner has also served on the board of managers of Swarthmore College where at various times he has served on its executive committee, finance committee, audit committee, academic affairs committee, student affairs committee, and property committee. In 2013 until 2015 Mr. Turner served on the board of directors of the Linda Crnic Institute for Down Syndrome at the University of Colorado Medical School. Mr. Turner has an M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in molecular biology from the University of Colorado and a B.A. in chemistry from Swarthmore College. - Joseph L. Turner，任2010年7月以来，担任我们的董事会成员。目前，他担任Corcept Therapeutics公司、Kythera Biopharmaceuticals公司和Sophiris生物制药公司的董事会和审计委员会主席。2012年，他担任Allos Therapeutics上市医药公司的董事会和审计委员会的主席，直到2012年9月它被Spectrum Pharmaceuticals公司收购。从2010年到2012年，他担任QLT上市生物科技公司的董事会和审计委员会的成员。2008年，他担任SGX Pharmaceuticals上市医药公司的董事和审计委员会成员。1999年，他加入Myogen生物制药上市公司，担任首席财务官，直到2006年它被吉利德科技公司收购。之前，他担任Centaur Pharmaceuticals公司的首席财务官，Cortech公司的首席财务官和副董事长。自2009年以来，他曾在斯沃斯莫尔学院的担任董事会主席，2010年6月，他加入财政委员会、学术事务委员会和学生事务委员会。2013年6月，他是财产委员会成员。2013年，他加入科罗拉多大学医学院琳达Crnic唐氏综合症研究所的董事会。他获得北卡罗莱纳大学教堂山分校的工商管理硕士学位，科罗拉多大学的分子生物学硕士学位、斯沃斯莫尔学院的化学学士学位。
- Joseph L. Turner has served as a member of our Board of Directors since February 2017. Mr. Turner currently serves on the board of directors of Arcutis Biotherapeutics, Inc., a publicly traded biopharmaceutical company, and Rainier Therapeutics, Inc. Prior to joining our Board of Directors, Mr. Turner served on the boards of directors and was the chair of the audit committees of Corcept Therapeutics, Inc., a publicly traded pharmaceutical company, from 2012 to May 2016 Kythera Biopharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2008 until Kythera’s acquisition by Allergan Inc. October 2015 and Sophiris Bio, a publicly traded pharmaceutical company from 2013 to May 2016. From July 2010 until its acquisition by Grupo Ferrer Internacional, S.A. in June 2016 Mr. Turner served on the board of directors and as a chair of the audit committee of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company. In 2012 Mr. Turner served on the board of directors and as chair of the audit committee of Allos Therapeutics, Inc., a publicly traded pharmaceutical company, until its acquisition by Spectrum Pharmaceuticals Inc. in September 2012. From 2010 through 2012 he served on the board of directors and as a member of the audit committee of QLT Inc., a publicly traded biotechnology company. In 2008 Mr. Turner served as a director and member of the audit committee of SGX Pharmaceuticals Inc., a publicly traded pharmaceutical company. Mr. Turner served as chief financial officer at Myogen, Inc., a publicly traded biopharmaceutical company, from 1999 until it was acquired by Gilead Sciences in 2006. Previously, Mr. Turner was the chief financial officer at Centaur Pharmaceuticals, Inc. and served as chief financial officer and vice president, finance and administration at Cortech, Inc. Since 2009 Mr. Turner has also served on the board of managers of Swarthmore College where at various times he has served on its executive committee, finance committee, audit committee, academic affairs committee, student affairs committee, and property committee. In 2013 until 2015 Mr. Turner served on the board of directors of the Linda Crnic Institute for Down Syndrome at the University of Colorado Medical School. Mr. Turner has an M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in molecular biology from the University of Colorado and a B.A. in chemistry from Swarthmore College.
- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX, Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), and Ziopharm Oncology, Inc. (Nasdaq: ZIOP). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX, Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), and Ziopharm Oncology, Inc. (Nasdaq: ZIOP). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
高管简历
中英对照 | 中文 | 英文- Edwin S. Kamemoto
Edwin S. Kamemoto，他曾一直担任我们的执行副总裁，负责研发和质量（2015年4月28日以来）。他曾担任我们的高级副总裁，负责监管事务（2014年6月以来）。此前，他曾担任我们的副总裁，负责监管事务（2012年7月以来）。他于2006年3月加入公司，担任助理董事，负责监管职务。他于2007年1月被提拔为负责监管事务的董事，于2008年6月被提拔为负责监管事务的高级董事，还于2010年1月被提拔为负责监管事务的执行董事。从2004年9月到2006年3月，他曾担任CATO Research公司（合同研究组织）的顾问。从1995年到2004年，他曾担任Nektar Therapeutics公司（一个公开上市的生物制药公司）的多种科学和监管事务管理职位。他此前也曾担任Glycomed公司（上市生物制药公司）和Celtrix Pharmaceuticals公司（上市生物制药公司）的科学职务。他持有UCLA的生物化学博士学位，并完成了Stanford University的药理学系博士后研究。他持有the University of Hawaii的化学和生物学学士学位。
Edwin S. Kamemoto has served as our Executive Vice President, R&D, Regulatory and Quality since April 2015. Prior to April 2015 Dr. Kamemoto was our Senior Vice President, Regulatory Affairs since June 2014 and prior to that time, he was our Vice President, Regulatory Affairs since July 2012. Dr. Kamemoto joined the Company in March 2006 as Associate Director, Regulatory Affairs, and was promoted to Director, Regulatory Affairs in January 2007 to Senior Director, Regulatory Affairs in June 2008 and to Executive Director, Regulatory Affairs in January 2010. From September 2004 to March 2006 Dr. Kamemoto was a consultant for CATO Research, a contract research organization. From 1995 to 2004 he held various scientific and regulatory affairs managerial positions at Nektar Therapeutics, a publicly traded biopharmaceutical company. He also held previous scientific-related positions at Glycomed and Celtrix Pharmaceuticals, both publicly traded biopharmaceutical companies. Dr. Kamemoto received a Ph.D. in biochemistry from UCLA, completed a postdoctoral fellowship in the Department of Pharmacology at Stanford University and received a B.S. in chemistry and biology from the University of Hawaii.- Edwin S. Kamemoto，他曾一直担任我们的执行副总裁，负责研发和质量（2015年4月28日以来）。他曾担任我们的高级副总裁，负责监管事务（2014年6月以来）。此前，他曾担任我们的副总裁，负责监管事务（2012年7月以来）。他于2006年3月加入公司，担任助理董事，负责监管职务。他于2007年1月被提拔为负责监管事务的董事，于2008年6月被提拔为负责监管事务的高级董事，还于2010年1月被提拔为负责监管事务的执行董事。从2004年9月到2006年3月，他曾担任CATO Research公司（合同研究组织）的顾问。从1995年到2004年，他曾担任Nektar Therapeutics公司（一个公开上市的生物制药公司）的多种科学和监管事务管理职位。他此前也曾担任Glycomed公司（上市生物制药公司）和Celtrix Pharmaceuticals公司（上市生物制药公司）的科学职务。他持有UCLA的生物化学博士学位，并完成了Stanford University的药理学系博士后研究。他持有the University of Hawaii的化学和生物学学士学位。
- Edwin S. Kamemoto has served as our Executive Vice President, R&D, Regulatory and Quality since April 2015. Prior to April 2015 Dr. Kamemoto was our Senior Vice President, Regulatory Affairs since June 2014 and prior to that time, he was our Vice President, Regulatory Affairs since July 2012. Dr. Kamemoto joined the Company in March 2006 as Associate Director, Regulatory Affairs, and was promoted to Director, Regulatory Affairs in January 2007 to Senior Director, Regulatory Affairs in June 2008 and to Executive Director, Regulatory Affairs in January 2010. From September 2004 to March 2006 Dr. Kamemoto was a consultant for CATO Research, a contract research organization. From 1995 to 2004 he held various scientific and regulatory affairs managerial positions at Nektar Therapeutics, a publicly traded biopharmaceutical company. He also held previous scientific-related positions at Glycomed and Celtrix Pharmaceuticals, both publicly traded biopharmaceutical companies. Dr. Kamemoto received a Ph.D. in biochemistry from UCLA, completed a postdoctoral fellowship in the Department of Pharmacology at Stanford University and received a B.S. in chemistry and biology from the University of Hawaii.
- Thomas B. King
Thomas B. King， 2003年6月以来，担任总裁、首席执行官以及董事会的成员。从2002年9月到2003年4月，担任Cognetix生物制药开发公司的主席、首席执行官和董事会成员。从1994年1月至2001年2月，他担任Anesta上市医药公司的各种高管职位；从1997年1月至2000年10月，他担任董事长和首席执行官，他是董事会的成员，直到它被Cephalon生物制药上市公司收购。他获得堪萨斯大学的工商管理硕士学位和麦克弗森学院的化学学士学位。
Thomas B. King has served as a director of the Company since May 24 2017. Mr. King served as the interim Chief Executive Officer of the Company from December 31 2017 to April 30 2018 and as interim President of the Company from April 30 2018 to May 30 2018. He has served as an independent biotechnology consultant and advisor since August 2016. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc., Faraday Pharmaceuticals, Inc. and Satsuma Pharmaceuticals, Inc., all privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.- Thomas B. King， 2003年6月以来，担任总裁、首席执行官以及董事会的成员。从2002年9月到2003年4月，担任Cognetix生物制药开发公司的主席、首席执行官和董事会成员。从1994年1月至2001年2月，他担任Anesta上市医药公司的各种高管职位；从1997年1月至2000年10月，他担任董事长和首席执行官，他是董事会的成员，直到它被Cephalon生物制药上市公司收购。他获得堪萨斯大学的工商管理硕士学位和麦克弗森学院的化学学士学位。
- Thomas B. King has served as a director of the Company since May 24 2017. Mr. King served as the interim Chief Executive Officer of the Company from December 31 2017 to April 30 2018 and as interim President of the Company from April 30 2018 to May 30 2018. He has served as an independent biotechnology consultant and advisor since August 2016. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc., Faraday Pharmaceuticals, Inc. and Satsuma Pharmaceuticals, Inc., all privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.